Guardant Health - GH Competitors

Guardant Health (NASDAQ:GH) and Veracyte (NASDAQ:VCYT) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, earnings, dividends, profitability, institutional ownership, community ranking, risk and valuation.

Does the media refer more to GH or VCYT?

In the previous week, Guardant Health and Guardant Health both had 2 articles in the media. Guardant Health's average media sentiment score of 1.43 beat Veracyte's score of 0.46 indicating that Guardant Health is being referred to more favorably in the media.

Company	Overall Sentiment
Guardant Health	Positive
Veracyte	Neutral

Do institutionals & insiders hold more shares of GH or VCYT?

90.4% of Guardant Health shares are owned by institutional investors. 5.9% of Guardant Health shares are owned by company insiders. Comparatively, 2.9% of Veracyte shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Which has more risk and volatility, GH or VCYT?

Guardant Health has a beta of 0.86, meaning that its stock price is 14% less volatile than the S&P 500. Comparatively, Veracyte has a beta of 1.44, meaning that its stock price is 44% more volatile than the S&P 500.

Is GH or VCYT more profitable?

Veracyte has a net margin of -12.33% compared to Guardant Health's net margin of -145.61%. Veracyte's return on equity of -3.42% beat Guardant Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Guardant Health	-145.61%	-242.65%	-35.89%
Veracyte	-12.33%	-3.42%	-3.18%

Which has higher valuation and earnings, GH or VCYT?

Veracyte has lower revenue, but higher earnings than Guardant Health. Veracyte is trading at a lower price-to-earnings ratio than Guardant Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Guardant Health	$449.54 million	5.39	-$654.59 million	-$6.40	-3.69
Veracyte	$296.54 million	5.22	-$36.56 million	-$0.50	-42.94

Do analysts rate GH or VCYT?

Guardant Health currently has a consensus price target of $57.64, indicating a potential upside of 144.35%. Veracyte has a consensus price target of $30.20, indicating a potential upside of 40.66%. Given Guardant Health's stronger consensus rating and higher probable upside, equities analysts plainly believe Guardant Health is more favorable than Veracyte.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Guardant Health	0 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.85
Veracyte	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

Does the MarketBeat Community prefer GH or VCYT?

Veracyte received 175 more outperform votes than Guardant Health when rated by MarketBeat users. Likewise, 73.26% of users gave Veracyte an outperform vote while only 68.61% of users gave Guardant Health an outperform vote.

Company	Underperform	Outperform
Guardant Health	Outperform Votes 247 68.61%	Underperform Votes 113 31.39%
Veracyte	Outperform Votes 422 73.26%	Underperform Votes 154 26.74%

Summary

Guardant Health beats Veracyte on 9 of the 17 factors compared between the two stocks.